Erectile dysfunction and ischaemic heart disease

Abdalla Ibrahim, Mohamed Ali, Thomas J. Kiernan, Austin G. Stack

Research output: Contribution to journalArticlepeer-review

Abstract

Erectile dysfunction (ED) is a common disorder that affects the quality of life of many patients. It is prevalent in more than half of males aged over 60 years. Increasing evidence suggests that ED is predominantly a vascular disorder. Endothelial dysfunction seems to be the common pathological process causing ED. Many common risk factors for atherosclerosis such as diabetes, hypertension, smoking, obesity and hyperlipidaemia are prevalent in patients with ED and so management of these common cardiovascular risk factors can potentially prevent ED. Phosphodiesterase type 5 inhibitors provide short-term change of haemodynamic factors to help initiate and maintain penile erection. They have been shown to be an effective and safe treatment strategy for ED in patients with heart disease, including those with ischaemic heart disease and hypertension.

Original languageEnglish
Pages (from-to)98-103
Number of pages6
JournalEuropean Cardiology Review
Volume13
Issue number2
DOIs
Publication statusPublished - 1 Dec 2018
Externally publishedYes

Keywords

  • Atherosclerosis
  • Endothelial dysfunction
  • Erectile dysfunction
  • Ischaemic heart disease
  • Phosphodiesterase inhibitors

Fingerprint

Dive into the research topics of 'Erectile dysfunction and ischaemic heart disease'. Together they form a unique fingerprint.

Cite this